|
|
Article: Five New Drugs for the Treatment of Generalized Anxiety Disorder Will Arrive to Market by 2008; A New Study from Decision Resources Also Finds That 50% of Patients Suffer from a Comorbid Psychiatric Condition That Masks the General Anxiety Disorder.
- Article from:
- PR Newswire
- Article date:
- September 22, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that five new drugs for generalized anxiety disorder (GAD) will arrive to market by 2008. Those expected to gain marketing approval for GAD by 2008 include Pfizer's pregabalin, Lundbeck/Forest Laboratories' escitalopram, Indevus Pharmaceutical's pagoclone, Dov Pharmaceuticals/Elan's ocinaplon, and Eli Lilly's LY-354740 pro-drug. In contrast, in 2002 only two drugs--GlaxoSmithKline's Paxil/Seroxat and Wyeth's Effexor XR--were specifically approved for treatment of GAD, according to a new ...